

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 316 630
A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88117847.9

(22) Date of filing: 26.10.88

(51) Int. Cl.4: C07C 87/50 , C07C 131/00 ,
C07D 239/42 , C07D 239/96 ,
C07D 209/40 , A61K 31/165 ,
A61K 31/505 , A61K 31/40

(30) Priority: 27.10.87 US 113789
18.12.87 US 134725
26.09.88 US 248204

(43) Date of publication of application:
24.05.89 Bulletin 89/21

(54) Designated Contracting States:
ES GR

(71) Applicant: WARNER-LAMBERT COMPANY
201 Tabor Road
Morris Plains New Jersey 07950(US)

(72) Inventor: Connor, David Thomas
2453 Antietam
Ann Arbor Michigan 48105(US)
Inventor: Flynn, Daniel Lee
17 North Bristol Court
Mundelein Illinois 60060(US)

(74) Representative: Mansmann, Ivo
c/o Gödecke AG - Patentabteilung Postfach
569 - Mooswaldallee 1-9
D-7800 Freiburg(DE)

(56) Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibiti n.

(57) The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenas and cyclooxygenase inhibiting properties; pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods for treating these conditions in mammals, including humans suffering therefor.

EP 0 316 630 A1

Express Mail No. EF378128674US
PD-A0000100-01-SMH


NOVEL FENAMIC ACID HYDROXAMATE DERIVATIVES HAVING CYCLOOXYGENASE AND 5-LIPOX- YGENASE INHIBITION

This application is a continuation-in-part of United States Application Serial Number 134,725, filed December 18, 1987, which is a continuation-in-part of United States Application Serial Number 113,789, filed October 27, 1987.

BACKGROUND OF THE INVENTION


The present invention is novel derivatives of fenamic acids. Such fenamic acids include mefenamic acids of U.S. Patent No. 3,138,636; flufenamic acids of U.S. Patent No. 3,144,387; meclofenamate and tolfenamic acids of U.S. Patent No. 3,313,848; and niflumic acids, flunixin, and clonixin of U.S. Patent No. 2,685,555.

Other anthranilic acid derivatives of the fenamic series previously known include the generic compounds of the British Patent No. 989,951 or formula




wherein Ar is α,α,α -trifluoro-m-tolyl; 2,3-xylyl, or 2,6-dichloro-m-tolyl, in U.S. Patent No. 3,852,333.

The present novel derivatives include selected hydroxamic acids thereof which are heretofore unknown. Among related aminobenzhydroxamic acids previously disclosed are compounds of the formula




wherein R' is a saturated fatty hydrocarbon radical; phenyl, phenylalkyl, wherein the rings are optionally substituted by lower alkyl or lower alkoxy; or an aromatic heterocyclic group. This disclosure is in Japanese Application 24578/67, filed April 2, 1964 by the Takeda Chemical Industry Co., Ltd. as an o-aminobenzhydroxamic acid analgesic, derivative having less toxicity and analgesic, antitarrhic, and antifebrile activity.

Other related disclosures include U.S. Patent No. 4,029,815 to compounds of the formula




wherein X_5 is trifluoromethyl, difluoromethyl, or nitro, X_4 is H, Br, Cl, or nitro, and Q may be NHOH. These compounds have utility as antidiarrheal agents.

Cyclized o-aminobenzhydroxamic-O-methylesters of the formula




wherein R' is alkyl, aralkyl, or a basic side chain and R'' is H, Cl, or Br; are disclosed by Wolf, E. and Kohl, H. in "Cyclisierungsreaktionen von am Aminostickstoff Substituierten o-Aminobenzhydroxamsäure-O-methylesteren," Ann. Chem. Liebigs, 1975, 1245-1251.

Wolf and Kohl also disclose an intermediate hydroxamic acid derivative from which the cyclized o-aminobenzhydroxamic-O-methylesters are made. The intermediate is




wherein R_c , R_e , and R_d are as defined below.


Other cyclized o-aminobenzhydroxamic acids disclosed are



or



wherein R_e is $\text{CH}_2\text{CO}_2\text{C}_2\text{H}_5$, $\text{C}_6\text{H}_4\text{Cl(p)NO}_2\text{(m)}$ and suggesting that R_e may also be $\text{SO}_2\text{C}_6\text{H}_4\text{CH}_3\text{(p)}$; and



wherein R_b is H or phenyl; R_c is H, $\text{CH}_2\text{C}_6\text{H}_5$, $\text{C}_6\text{H}_4\text{Cl}(p)$, $\text{CH}_2\text{C}_6\text{H}_4\text{Cl}(p)$, C_6H_5 , or CH_3 ; R_e is H or NO_2 ; and R_d is H or Cl. However, Wolf and Kohl do not disclose activity for these cyclized compounds and, further, do not make obvious the present invention.

Broadly, hydroxamic acid derivatives of selected aryl ring systems are disclosed in European Application Publication No. 0 196 184 having surprisingly high potency particularly by inhalation, oral efficacy, and with a surprisingly long duration of action. However, these aryl ring systems are in no way related to the present fenamic acid type compounds.

Two disclosures by Summers et al, (1) *J. Med. Chem.*, 1987, 30, 574-80 and (2) *In Vivo Characterization of Hydroxamic Acid Inhibitors of 5-Lipoxygenase* disclosed at a seminar in early September, 1987 (Abstract) disclose hydroxamic acids as inhibitors of 5-lipoxygenase, however, the disclosures do not extend beyond very limited representative examples not including any fenamic acid derivatives.

Additional references related to the present invention, particularly for the substituents therein for L_1 and L_2 , include a disclosure for reduction of the substituent in the carboxy-containing side chain of anilinophenyl group in J55013-227 of Derwent Abstract No. 17678C/10; and various fused nitrogen-containing ring systems in J54151-963 in Derwent Abstract No. 02846C/02, J54073-771 in Derwent Abstract No. 55094B/30, J54073-750 in Derwent Abstract No. 550855/30, J54073-737 in Derwent Abstract No. 55078B/30, J54070-265 in Derwent Abstract No. 51907B/28, J54063-073 in Derwent Abstract No. 48163B/26, J54063-042 in Derwent Abstract No. 48147B/26, DL-134-520 in Derwent Abstract No. 39059B/21, and JA2489/67 in Derwent Abstract No. 29861, U.S. Patent No. 3,325,499 in Derwent Abstract No. 27,108 and 3,317,524 in Derwent Abstract No. 26,495.


Also in CA73(2):10333g 1-phenyl-3-isatinoxime is disclosed. The compounds disclosed in each of these references is not now the present invention because the particular substituents noted as L_1 and NOR_7 found in the present invention are not included or made obvious from the references.

Thus, the present invention are to selected novel derivatives of fenamates and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions for treating inflammation, arthritis, pain, pyrrhia, and the methods for such treatment.

Finally, known related cyclized compounds include the quinazolinone derivatives disclosed in U.S. Patent No. 3,794,643 which are different from the present cyclized derivatives by unobvious substituents, particularly at the nitrogen between the ring carbonyls.


SUMMARY OF THE INVENTION

The present invention is a novel compound of the formula (I)




15 wherein

(1) R₁ is




25 wherein R₆ is hydrogen, lower alkyl, aryl, aralkyl, or cycloalkyl of from three to ten carbons having three to seven ring carbons; R₇ is independently H, lower alkyl, or acyl; and R₈ is H or lower alkyl; with the proviso that when



R₇ cannot be methyl when R₅ is para-chloro and R₃ and R₄ are hydrogen, and (iii) as defined together with R₂ below;

35 (2) —R₂ is H, lower alkyl, or taken together with —R₁ is



45 wherein L₁ is oxygen or H₂; and R₇ is independently as defined above; and


(3) R₃, R₄, R₅, and R₁₁ are independently hydrogen, fluoro, chloro, bromo, trifluoromethyl, lower alkyl, CN, hydroxy, lower alkoxy, —S(O)_n-lower alkyl, NO₂, or NR₉R₁₀ wherein R₉ and R₁₀ are independently H, lower alkyl, or acyl and n is an integer of 0 through 2, with

50 the further proviso that when R₁ is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{NHOH} \end{array}$ then R₃, R₄, or R₅ cannot all be hydrogen or then one or two of R₃, R₄, or R₅ cannot be alkyl when the other one or two of R₃, R₄, or R₅ is hydrogen, and when R₁ is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{NHOH} \end{array}$ and one of R₃, R₄, or R₅ is ortho-alkyl then one other of R₃, R₄, or R₅ cannot be meta-nitro, meta-difluoromethyl, or meta-trifluoromethyl when R₁₁ is H, Br, Cl, or nitro and pharmaceutically acceptable acid addition or base salts thereof.

55

The present invention is also a pharmaceutical composition for the treatment of conditions advanta-

geously affected by the inhibition of 5-lipoxygenase and/or cyclooxygenase which comprises administering an amount effective for inhibiting 5-lipoxygenase and/or cyclooxygenase of a novel compound of the formula (I)




wherein

20 (1) R_1 is



wherein R_6 is hydrogen, lower alkyl, aryl, aralkyl, or cycloalkyl of from three to ten carbons having three to seven ring carbons; R_7 is independently H, lower alkyl, or acyl; and R_8 is H or lower alkyl; and as defined together with R_2 below;


30 (2) $\text{---} \text{C} \text{---}$ R_2 is H, lower alkyl, or taken together with $\text{---} \text{C} \text{---}$ R_1 is



40 wherein L_1 is oxygen or H_2 ; and R_7 is independently as defined above; and

(3) R_3 , R_4 , R_5 , and R_{11} are independently hydrogen, fluoro, chloro, bromo, trifluoromethyl, lower alkyl, CN, hydroxy, lower alkoxy, $-S(O)_n$ -lower alkyl, NO_2 , or NR_9R_{10} or NO_2 wherein R_9 and R_{10} are independently H, lower alkyl, or acyl; and n is an integer of 0 through

45 2; with the proviso that when R_1 is



$\text{---} \text{C} \text{---}$ NH_2 and one of R_3 , R_4 , or R_5 is ortho-alkyl then one other of R_3 , R_4 , or R_5 cannot be meta-nitro, meta-difluoromethyl, or meta-trifluoromethyl when R_{11} is H, Br, Cl, or NO_2 ; and pharmaceutically acceptable acid addition or base salts thereof and a pharmaceutically acceptable carrier.

Further, the present invention also provides a method of use for a composition of a compound of the formula (I), as defined herein before, or physiologically acceptable acid addition or base salt thereof for use as an inhibitor of the lipoxygenase and/or cyclooxygenase enzymes of the mammalian including human arachidonic acid metabolism, which method comprises inhibition of such enzymes by administration to a mammal of a lipoxygenase and/or cyclooxygenase inhibiting amount of any such compound or salt in unit

dosage form, and to use of any such compound or salt in the manufacture of lipooxygenase and/or cyclooxygenase inhibitor agents.

Further, the present invention also provides any compound or composition of formula (I) (as hereinbefore defined) or physiologically acceptable salt thereof, for use as a medical therapeutic and/or prophylactic agent, to methods of medical therapeutic and/or prophylactic treatment by administration to a mammal of a medically therapeutic and/or prophylactic effective amount of any such compound or salt, and to use of any such compound or salt in the manufacture of medical therapeutic and/or prophylactic agents. The kinds of medical therapy and prophylaxis pertinent to the foregoing and therefore in that sense comprising part of the present invention, are elaborated by way of example in the following paragraphs which are not intended to be construed as in any way limiting the scope of these aspects of said invention.


The most preferred compound of the present invention is 1-(2,6-dichloro-3-methylphenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, which is shown in Example 35 hereinafter.

DETAILED DESCRIPTION OF THE INVENTION

In the compounds of formula (I) the term "lower alkyl" is meant to include a straight or branched alkyl group having one to four carbon atoms, such as, for example, methyl, ethyl, propyl, or butyl, and isomers thereof.

Lower alkoxy is O-alkyl or of from one to four carbon atoms as defined above for "lower alkyl".

Acyl is a



-C(=O)-phenyl optionally substituted by a lower alkyl, fluoro, chloro, bromo, trifluoromethyl, hydroxy, or lower alkoxy; and wherein the lower alkyl is as defined above.

Cycloalkyl of from three to ten carbons having from three to seven ring carbons includes cyclopropyl, cyclobutyl, methylcyclobutyl, ethylcyclobutyl, dimethylcyclobutyl, cyclopentyl, and the like.

Aryl is phenyl unsubstituted and substituted with from one to three substituents selected from the group consisting of hydroxy, lower alkoxy, fluoro, chloro, bromo, trifluoromethyl, lower alkyl, CN, -S(O)_n lower alkyl wherein n is as defined above, NO₂, or NR₁R₁₀ wherein R₁ and R₁₀ are independently as defined above.

An aralkyl is an aryl as defined above attached through a lower alkylene wherein the alkylene is of from one to four carbons such as methylene, 1,2-ethylenyl, 1,1-ethylenyl, propylene, and the like.

Appropriate compounds of formula (I) are useful in the free base form, in the form of base salts where possible, and in the form of acid addition salts. The three forms are within the scope of the invention. In practice, use of the salt form amounts to use of the base form. Pharmaceutically acceptable salts within the scope of the invention may be those derived from mineral acids such as hydrochloric acid and sulfuric acid; and organic acids such as ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like, giving the hydrochloride, sulfamate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and the like, respectively or those derived from bases such as suitable organic and inorganic bases. Examples of pharmaceutically acceptable base addition salts with compounds of the present invention include organic bases which are nontoxic and strong enough to form such salts. These organic bases form a class whose limits are readily understood by those skilled in the art. Merely for purposes of illustration, the class may be said to include mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and triethylamine; mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine; amino acids such as arginine, and lysine; guanidine; N-methylglucosamine; N-methylglucamine; L-glutamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; tris(hydroxymethyl)aminomethane; and the like. (See for example, "Pharmaceutical Salts," J. Pharm. Sci., 66(1):1-19 (1977).) Salts of inorganic bases include sodium, potassium, calcium or the like.

The acid addition salts of said basic compounds are prepared either by dissolving the free base or acid of compound I in aqueous or aqueous alcohol solution or other suitable solvents containing the appropriate acid or base and isolating the salt by evaporating the solution, or by reacting the free base of compound I with an acid as well as reacting compound I having an acid group thereon with a base such that the reactions are in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

The compounds of the invention may contain an asymmetric carbon atom. Thus, the invention includes

th individual stereoisomers, and mixtures thereof. The individual isomers may be prepared or isolated by methods known in the art.

By virtue of their lipooxygenase inhibitory properties, said compounds and salts find application in the treatment and/or prophylaxis of any condition where a lipooxygenase inhibitor is indicated, especially spasmogenic and allergic conditions, psoriasis, and as utility in cytoprotection.

By virtue of their cyclooxygenase inhibitory properties, said compounds and salts find application in the treatment and/or prophylaxis of any condition where a cyclooxygenase inhibitor is indicated, especially pyresis, pain, and inflammation.

By virtue of both their lipooxygenase and cyclooxygenase inhibitory properties, said compounds and salts find application in the treatment and/or prophylaxis of any condition where a dual lipooxygenase/cyclooxygenase inhibitor is indicated, especially any condition involving blood platelet aggregation or inflammation. In the case of inflammation, the compounds and salts are particularly suited to the treatment and/or prophylaxis of conditions associated with infiltration of leukocytes into inflamed tissue.

In determining when a lipooxygenase, cyclooxygenase, or dual lipooxygenase/cyclooxygenase inhibitor is indicated, of course inter alia, the particular condition in question and its severity, as well as, the age, sex, weight, and the like of the subject to be treated, must be taken into consideration and this determination is ultimately at the discretion of the attendant physician.

Examples of the aforesaid spasmogenic conditions are those involving smooth muscle tissue, especially airway smooth muscle constriction such as intrinsic asthma—including intrinsic or idiopathic bronchial asthma and cardiac asthma), bronchitis and arterial smooth muscle constriction such as coronary spasm (including that associated with myocardial infarction, which may or may not lead to left ventricular failure resulting in cardiac asthma) and cerebral spasm or 'stroke'. Other examples include bowel disease caused by abnormal colonic muscular contraction such as may be termed 'irritable bowel syndrome', 'spastic colon', or 'mucous colitis'.

Examples of the aforesaid allergic conditions are extrinsic asthma (from which it will be appreciated that said compounds and salts are particularly favorable as antiasthmatic agents), allergic skin diseases such as eczema having a total or partial allergic origin, allergic bowel disease (including coeliac disease) and allergic eye conditions such as hay fever (which may additionally or alternatively affect the upper respiratory tract) and allergic conjunctivitis. Examples of the aforesaid tumors are skin neoplasms, both benign and malignant.

Examples of the aforesaid pyretic and painful conditions include fever associated with infections, trauma and injury, malignant disease, and diseases affecting the immune system (including autoimmune diseases).

Examples of the aforesaid conditions involving blood platelet aggregation are those resulting from thrombosis, including 'stroke' having a total or partial thrombotic origin, coronary thrombosis, phlebitis, and phlebothrombosis (the latter two conditions also possibly being associated with inflammation).

Examples of the aforesaid conditions involving inflammation are inflammatory conditions of the lung, joints, eye, bowel, skin, and heart.

Inflammatory lung conditions which may be so treated and/or prevented include asthma and bronchitis (vide supra) and cystic fibrosis (which may also or alternatively involve the bowel or other tissue).

Inflammatory joint conditions which may be so treated and/or prevented include rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, and other arthritic conditions.

Inflammatory eye conditions which may be so treated and/or prevented include uveitis (including iritis) and conjunctivitis (vide supra).

Inflammatory bowel conditions which may be so treated and/or prevented include Crohn's disease, ulcerative colitis, and ischemic bowel disease.

Inflammatory skin diseases which may be so treated and/or prevented include those associated with cell proliferation, such as psoriasis and eczema (vide supra) and dermatitis (whether or not of allergic origin).

Inflammatory conditions of the heart which may be so treated and/or prevented include coronary infarct damage.

Other inflammatory conditions which may be so treated and/or prevented include tissue necrosis of chronic inflammation and tissue rejection following transplant surgery.

It is also believed that the compound of formula (I) and their physiologically acceptable salts or effective agents in the prophylaxis and/or treatment of bacterial and fungal infections, thus forming a further aspect of the present invention in like manner.

For medical use, the amount required of a compound of formula (I) or physiologically acceptable salt thereof—(hereinafter referred to as the active ingredient) to achieve a therapeutic effect will, of course, vary both with the particular compound, the route of administration and the mammal under treatment and the

particular disorder or disease concerned. A suitable dose of a compound of formula (I) or physiologically acceptable salt thereof for a mammal suffering from, or likely to suffer from any condition as described hereinbefore is 0.1 μ g-500 mg of base per kilogram body weight. In the case of systemic administration, the dose may be in the range 0.5 to 500 mg of base per kilogram body weight, the most preferred dosage being 0.5 to 50 mg/kg of mammal body weight for Example 5 to 25 mg/kg; administered two or three times daily. In the case of topical administration, e.g. to the skin or eye, a suitable dose may be in the range 0.1 ng-100 μ g of base per kilogram, typically about 0.1 μ g/kg.

In the case of oral dosing for the treatment or prophylaxis of airway smooth muscle constriction, or asthma, or bronchitis in general, due to any cause, a suitable dose of a compound of formula (I) or physiologically acceptable salt thereof, may be as specified in the preceding paragraph, but most preferably is from 1 mg to 10 mg of base per kilogram, the most preferred dosage being from 1 mg to 5 mg/kg of mammal body weight, for example from 1 to 2 mg/kg. In the case of pulmonary administration for the latter indications, the dose may be in the range of from 2 μ g to 100 mg, for example from 20 μ g to 0.5 mg, especially 0.1 to 0.7 mg/kg.

It is understood that the ordinarily skilled physician or veterinarian will readily determine and prescribe the effective amount of the compound to prevent or arrest the progress of the condition for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low doses at first, subsequently increasing the dose until a maximum response is obtained.

While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation comprising a compound of formula (I) or a pharmacologically acceptable acid addition salt thereof and a physiologically acceptable acid addition salt thereof and a physiologically acceptable carrier therefor. Such formulations constitute a further feature of the present invention. Conveniently, the active ingredient comprises from 0.1% to 99.9% by weight of the formulation. Conveniently, unit doses of a formulation contain between 0.1 mg and 1 g of the active ingredient. For topical administration, the active ingredient preferably comprises from 1% to 2% by weight of the formulation but the active ingredient may comprise as much as 10% w/w. Formulations suitable for nasal or buccal administration, (such as self-propelling powder dispensing formulations described hereinafter), may comprise 0.1 to 20% w/w, for example 2% w/w of active ingredient.

The formulations, both for veterinary and for human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefor and optionally other therapeutic ingredient(s). The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

The formulations include those in a form suitable for oral, pulmonary, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), intraarticular, topical, nasal, or buccal administration.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

Formulations of the present invention suitable for oral administration may be in the form of discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or nonaqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient may also be in the form of a bolus, electuary, or paste.

A tablet may be made by compressing or molding the active ingredient optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active, or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered active ingredient and a suitable carrier moistened with an inert liquid diluent.

Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.

Formulations suitable for intraarticular administration may be in the form of a sterile aqueous preparation of the active ingredient which may be in microcrystalline form, for example, in the form of an aqueous

microcrystalline suspension. Liposomal formulations or biodegradable polymer systems may also be used to present the active ingredient for both intraarticular and ophthalmic administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applications, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops. For example, for ophthalmic administration, the active ingredient may be presented in the form of aqueous eye drops as, for example, a 0.1-1.0% solution. Formulations suitable for administration to the nose or buccal cavity include powder, self-propelling and spray formulations such as aerosols and atomizers. The formulations, when dispersed, preferably have a particle size in the range of 0.1 to 200 μ .

A particularly valuable form of a pharmaceutical composition of the present invention, for use in the prophylaxis or treatment of airway smooth muscle constriction, or asthma or bronchitis in general, due to any cause, is one suitable for pulmonary administration via the buccal cavity. Preferably the composition is such that particles having a diameter of 0.5 to 7 μ , most preferably 1 to 6 μ , containing active ingredient, are delivered into the lungs of a patient. Such compositions are conveniently in the form of dry powders for administration from a powder inhalation device or self-propelling powder-dispensing containers, for example as a self-propelling aerosol composition in a sealed container; preferably the powders comprise particles containing active ingredient of which particles at least 98% by weight have a diameter greater than 0.5 μ and at least 95% by number have a diameter less than 7 μ . Most desirably at least 95% by weight of the particles have a diameter greater than 1 μ at least 90% by number of the particles have a diameter less than 6 μ .

The compositions in the form of dry powders preferably include a solid fine powder diluent such as sugar and are conveniently presented in a permeable capsule, for example of gelatin.

Self-propelling compositions of the invention may be either powder-dispensing compositions or compositions dispensing the active ingredient in the form of droplets of a solution or suspension. Self-propelling powder-dispensing compositions include a liquid propellant having a boiling point of below 65° F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% w/w of the composition whilst the active ingredient may constitute 0.1 to 20% w/w, for example about 2% w/w of the composition. The carrier in such compositions may include other constituents, in particular a liquid nonionic or solid anionic surfactant, or a solid diluent (preferably having a particle size of the same order as of the particles of active ingredient) or both. The surfactant may constitute from 0.01 up to 20% w/w, though preferably it constitutes below 1% w/w of the composition.

Self-propelling compositions wherein the active ingredient is present in solution comprise an active ingredient, propellant, and co-solvent, and advantageously an antioxidant stabilizer. The co-solvents may constitute 5 to 40% w/w of the composition, though preferably less than 20% w/w of the composition.

Compositions of the present invention may also be in the form of aqueous or dilute alcoholic solution, optionally a sterile solution, of the active ingredient for use in a nebulizer or atomizer.

Formulations of the present invention may also be in the form of an aqueous or dilute alcoholic solution, optionally a sterile solution, of the active ingredient for use in a nebulizer or atomizer, wherein an accelerated air stream is used to produce a fine mist consisting of small droplets of the solution. Such formulations usually contain a flavoring agent such as saccharin sodium and a volatile oil. A buffering agent and a surface active agent may also be included in such a formulation which should also contain a preservative such as methylhydroxybenzoate.

Other formulations suitable for nasal administration include a coarse powder having a particle size of 20 to 500 microns which is administered in the manner in which snuff is taken i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.

In addition to the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservatives e.g., methylhydroxybenzoate (including antioxidants), emulsifying agents, and the like. Any other therapeutic ingredient may comprise one or more of the following: antibiotic (e.g., antibacterial), antifungal and antiviral agents, and antihistamines (particularly peripherally acting antihistamines). However, when such other agent(s) are also present, according to another aspect of the invention, the compound of formula (I) or physiologically acceptable salt thereof and the other agent(s), need not necessarily be present as a pharmaceutical formulation as hereinbefore defined, but merely in combination or intimate admixture, i.e., optionally, a pharmaceutically acceptable carrier need not be present.


The combination with antihistamines is particularly favored for antiasthmatic use. Such an antihistamine may be selected from any compound described in European Patent Applications EP 0 859 949 A and EP 0 117 302 A. The amount and dosage regime for such an antihistamine may be chosen from any of those

recited in the latter two European Specifications. Especially preferred are the antihistamines (E)-3-(6-(3-pyrrolidino)-1-(4-tolyl)prop-1E-enyl-(2-pyridyl)) acrylic acid and (E)-3-(6-(3-pyrrolidino)-1-(4-tolyl)prop-1E-enyl-(2-pyridyl))propionic acid. Another preferred antihistamine is (E)-1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene, otherwise known as tyrolidine.


Also preferred is the antihistamine known as Seldane.

The compound of formula (I) and their salts may be prepared generally by the following processes and constitute a further aspect of the present invention.

For the preparation of compounds of the formula (I) wherein R_1 is




wherein R_6 and R_7 are as defined above,
a compound of the formula (II)



II

wherein R_2 , R_3 , R_4 , R_5 , and R_{11} are as defined above is converted to an acid chloride by treatment with oxalyl chloride, thionyl chloride, or the like to obtain the compound of formula (III)




III

wherein R_2 except not to be taken together with R_1 , R_3 , R_4 , R_5 , and R_{11} are as defined above;
the compound of formula (III) is then treated with the appropriately substituted hydroxylamine of the formula (IV)



IV


to obtain the compound of formula (I) wherein R_1 is



5


For the preparation of the compounds of formula (I) wherein R_1 is

10



or wherein R_1 is taken together with R_2 and is

15




20

wherein R_6 , R_7 , R_8 , and L_1 are as defined above;

(1) A compound of the formula (X)

25



X


30

35

is prepared by decarboxylating the compound of formula (II) wherein R_2 is hydrogen and R_3 , R_4 , R_5 , and R_1 are as defined above; then


(2) the compound of the formula (X) is treated with a compound of the formula

40



to obtain the compound of the formula (XI)

45




XI

50

55


wherein R_3 , R_4 , R_5 , and R_{11} are as defined above; using conditions analogous to those in U.S. Patent No. 4,092,430 then

- (3) the compound of formula (XI) is treated with a Lewis acid such as $AlCl_3$, BF_3 , or the like, preferably $AlCl_3$; to cyclize the compound (XI) to the compound of the formula (I_b) where in L_2 is oxygen which can optionally be further treated with a compound of the formula H_2NOR_7 wherein R_7 is as defined above; to obtain the compound of formula (I_b)

I''_b


which is then optionally treated with a nucleophile of the formula $:R_8$

wherein R_8 is H or alkyl to obtain the compound of the formula (I) wherein R_1 is




wherein R_7 is H, lower alkyl, or acyl and R_8 is hydrogen or lower alkyl.

Finally, for the preparation of the compounds of the formula (I) wherein R_1 taken together with R_2 is




wherein L_1 is oxygen and R_7 is as defined above;

- (i) a compound of the formula (I) wherein R_1 is




wherein R_6 is hydrogen is reacted with a compound of the formula



5

to obtain a compound of the formula (I) wherein L_1 is oxygen and R_7 is as defined above.
For the preparation of the compounds of formula I wherein R_1 taken together with R_2 is


10



15

wherein L_1 is H_2 and R_7 is as defined above;
the compound of the formula (I) wherein R_1 is


20



25

wherein R_6 is hydrogen and R_7 is as defined above may be reacted with formaldehyde to obtain the compound of the formula (I) wherein R_1 and R_2 together are

30



35

wherein L_1 is H_2 and R_7 is as defined above.

40

The above reactions are shown in the following Schemes I, II, and III followed by details for selected steps.

45

50

55

Scheme I

5

10

15

20

25

30


35

40


45

50

55



Scheme II



Scheme III

6

10

15

20

25

30


35

40

45

50

55



Scheme IV

5

10

15

20

25


30

35

40

45

50



Scheme I

55

Step A:

Treatment of the compound of formula II with oxalyl chloride/DMF affords the acid chloride of formula

III, which is directly reacted with an appropriately substituted hydroxylamin HNR_6OR_7 to give rise to a compound of the formula I_6 .

Scheme II

Thermal decarboxylation of a compound of the formula II_6 by means of Cu/quinoline affords a compound of formula X, which is converted to the acid chloride of formula XI by treatment with oxalyl chloride. Cyclization of the compound of formula XI by means of a Lewis acid, preferably AlCl_3 , then gives rise to a compound of formula I_6 (see reference in the literature to analogous reactions).

Conversion of the compound of formula I_6 to the corresponding oxime analogues of formula I_6 is performed by treating the compound of formula I_6 with an approximately substituted hydroxylamine and an organic base (preferably triethylamine).

Ring opening of the compound of formula I_6 by means of hydroxide or alkoxide then affords a compound of formula I_6' .

Scheme III

The o-anilino hydroxamic acid of formula I_c is treated with phosgene and an appropriate base according to a procedure analogous to such procedures in the literature to give the cyclic analogues of formula I_c' . Alternatively, treatment of the o-anilino hydroxamic acid of formula I_c with formaldehyde under dehydrating conditions affords the cyclic analogues of formula I_c' .

Scheme IV

The several reactions of this scheme show other means to prepare the compounds of the present invention using analogous methods well known in the art from starting materials that are known or can be readily prepared by known methods and variously exemplified hereinafter.

One of skill in the art would recognize variations in the sequence and would recognize appropriate reaction conditions from analogous reactions which may be appropriately used in the processes to make the compounds of formula (I) herein. Further, the starting materials are known or can be prepared by known methods.

Under certain circumstances it is necessary to protect either the N or O of intermediates in the above noted process with suitable protecting groups which are known. Introduction and removal of such suitable oxygen and nitrogen protecting groups are well-known in the art of organic chemistry; see for example "Protective Groups in Organic Chemistry," J. F. W. McOmie, ed., (New York, 1973), pages 43ff, 95ff, J. F. W. McOmie, *Advances in Organic Chemistry*, Vol. 3, 191-281 (1963); R. A. Borssenas, *Advances in Organic Chemistry*, Vol. 3, 159-190 (1963); and J. F. W. McOmie, *Chem. & Ind.*, 603 (1979).

Examples of suitable oxygen protecting groups are benzyl, t-butyl dimethylsilyl, ethoxyethyl, and the like. Protection of an N-H containing moiety is necessary for some of the processes described herein for the preparation of compounds of this invention. Suitable nitrogen protecting groups are benzyl, triphenylmethyl, trialkylsilyl, trichloroethylcarbamate, trichloroethoxycarbonyl, vinyloxycarbamate, and the like.

Under certain circumstances it is necessary to protect two different oxygens with dissimilar protecting groups such that one can be selectively removed while leaving the other in place. The benzyl and t-butyl dimethylsilyl groups are used in this way; either is removable in the presence of the other, benzyl being removed by catalytic hydrogenolysis, and t-butyl dimethylsilyl being removed by reaction with, for example, tetra-n-butylammonium fluoride.

In the process described herein for the preparation of compounds of this invention the requirements for protective groups are generally well recognized by one skilled in the art of organic chemistry, and accordingly the use of appropriate protecting groups is necessarily implied by the processes of the charts herein, although not expressly illustrated.

The products of the reactions described herein are isolated by conventional means such as extraction, distillation, chromatography, and the like.

The salts of the compounds of formula (I) described above are prepared by reacting the appropriate base or acid with a stoichiometric equivalent of the compounds of formula (I), respectively, to obtain pharmaceutically acceptable salts thereof.

The invention is further elaborated by the representative examples as follows. Such examples are not meant to be limiting.

EXAMPLES

EXAMPLE 1

2-[(2,6-Dichloro-3-methylphenyl)amino]-N-hydroxy-N-phenylmethylbenzamide.

Meclomen (5.92 g; 0.02 mol) is suspended in CH_2Cl_2 (150 ml) containing DMF (1.46 g, 0.02 mol) and cooled to 0°C . Oxalyl chloride is added to the solution over 30 minutes and the resulting yellow solution is stirred at 24°C for 20 hours and then added to a cold solution of N-benzylhydroxylamine (2.46 g; 0.02 mol) in THF (60 ml) - H_2O (15 ml) - Et_3N (20 ml) mixture. The solution is allowed to come to 24°C and treated with 2N HCl (160 ml). The product is extracted with CH_2Cl_2 . The extracts are dried over sodium sulfate and evaporated to dryness. The residue is flash chromatographed through SiO_2 gel eluting with CH_2Cl_2 . The fractions containing the product are evaporated and the solid residue is recrystallized from isopropylether/n-hexane yielding white crystals. Yield 1.45 g (18.6%); mp $133-135^\circ\text{C}$.

EXAMPLE 2

Ortho-2,6-dichloro-3-methylanilinobenzhydroxamic acid or 2-[(2,6-dichloro-3-methylphenyl)amino]-N-hydroxybenzamide.

Ortho-2,6-dichloro-3-methylanilinobenzoic acid (3.0 g) is suspended in methylenechloride (75 ml) containing DMF (0.74 g). After cooling to 0°C , oxalyl chloride (2.8 g) is added dropwise. After the initial suspension dissolves, the solution is cannulated into an aqueous THF (125 ml THF/15 ml water) solution of hydroxylamine-HCl (2.8 g) and triethylamine (6.1 g). After stirring for thirty minutes at room temperature, the solution is then poured into 2 N aqueous HCl (300 ml). The organics are extracted into methylene chloride, dried (MgSO_4), and concentrated to afford a residue. Flash chromatography (230 mesh silica gel, 20% methylene chloride, 20% ethyl acetate, 60% hexane) affords 1.1 g (35% yield) of ortho-2,6-dichloro-3-methylanilinobenzhydroxamic acid, mp $170-175^\circ\text{C}$. Microanalysis: C, H, N

Calc.	C, 54.04;	H, 3.89;	N, 9.00
Found	C, 53.80;	H, 3.74;	N, 8.71.

Second run:

2-[(2,6-Dichloro-3-methylphenyl)amino]-N-hydroxybenzamide.

Yield: 23.35 g (62.6%); mp $158-159^\circ\text{C}$, recrystallized from ether/n-hexane.

The discrepancy in melting points between the first and second run appears to be a mechanical error in the first.

EXAMPLE 3

Ortho-2,6-dichloro-3-methylanilinobenz-N-methylhydroxamic acid or 2-[(2,6-dichloro-3-methylphenyl)amino]-N-hydroxy-N-methylbenzamide.

According to the procedure of Example 2, ortho-2,6-dichloro-3-methylanilinobenzoic acid (4.0 g) is reacted with N-methylhydroxylamine-HCl (4.5 g) to afford 2.1 g (47% yield) of ortho-2,6-dichloro-3-methylanilinobenz-N-methylhydroxamic acid, mp 117-124° C. Microanalysis: C, H, N

Calc.	C, 55.40;	H, 4.34;	N, 8.61
Found	C, 55.12;	H, 4.55;	N, 8.98.

Second run: Yield: 18.8 g (48%); mp 126-128° C, recrystallized from ether/n-hexane.

EXAMPLE 4

Ortho-2,6-dichloro-3-methylanilinobenzhydroxamic acid O-methyl ether or 2-[(2,6-dichloro-3-methylphenyl)amino]-N-methoxybenzamide.

According to the procedure of Example 2, ortho-2,6-dichloro-3-methylanilinobenzoic acid (3.0 g) is reacted with methoxylamine-HCl (3.4 g) to afford 2.0 g (61% yield) of ortho-2,6-dichloro-3-methylanilinobenzhydroxamic acid O-methyl ether, mp 210-214° C. Microanalysis: C, H, N

Calc.	C, 55.40;	H, 4.34;	N, 8.61
Found	C, 55.09;	H, 4.21;	N, 8.38.

Second run: Yield: 30.3 g (77.7%); mp 192-194° C, recrystallized from ethyl acetate.

The following compounds are prepared following the procedures analogous to those of Example 1 above using appropriate starting materials.

EXAMPLE 5

2-[(2,6-Dichloro-3-methylphenyl)amino]-N-hydroxy-N-1-methylethylbenzamide.

Yield: 5.35 g (38%); mp 152-153° C, recrystallized from acetonitrile.

EXAMPLE 6

2-[(2,3-dimethylphenyl)amino]-N-hydroxy-N-methylbenzamide.

1,1'-Carbonyl-diimidazole (5.35 g; 0.033 mol) is added to a solution of metanamic acid (7.24 g; 0.03 mol) in dry DMF (100 ml). The solution is stirred at 24° C for 20 hours and then briefly warmed to 50° C. N-Methylhydroxylamine hydrochloride (2.7 g; 0.032 mol) is added to the cooled solution at 24° C and stirred for two days. The reaction mixture is then evaporated to dryness and the residue is taken up in CH₂Cl₂, washed with water, and dried over sodium sulfate and evaporated. The residue is flash chromatographed through silica gel and eluted with n-hexane-CH₂Cl₂-EtOAc (2:1:1) yielding a crude product which is rechromatographed through silica gel and eluted with n-hexane-CH₂Cl₂-EtOAc (4:5:1). The product is recrystallized from n-pentane to give white crystals. Yield 1.5 g (18.5%); mp 70-71° C.

EXAMPLES 7-8

The following compounds are prepared following the procedures analogous to Example 6 as described above using appropriate starting materials.

2-[(2,3-Dimethylphenyl)amino]-N-methoxybenzamide.

Yield: 6.5 g (48%); mp 151-152 °C, recrystallized from ethyl acetate.

2-[(2,3-dimethylphenyl)amino]-N-hydroxy-N-(1-methylethyl)benzamide.

Yield: 6.08 g (78.4%); mp 47-49.5 °C, recrystallized from n-pentane.

EXAMPLE 9

2-[(2,3-dimethylphenyl)amino]-N-hydroxybenzamide.

Sodium methoxide (6.48 g; 0.12 mol) is added to a solution of metanamic acid methyl ester (5.11 g; 0.02 mol) and hydroxylamine·HCl (5.56 g; 0.08 mol) in methanol (450 ml) and THF (50 ml). The mixture is heated to reflux for 20 hours. An additional amount of hydroxylamine·HCl (1.39 g; 0.02 mol) and sodium methoxide (1.62 g; 0.03 mol) is added and the heating is continued for an additional three hours. The reaction mixture is cooled and quenched with AcOH (60 ml), diluted with water (300 ml), and concentrated to half the original volume. It is extracted with CH₂Cl₂, washed with water, and dried over sodium sulfate. Evaporation of the solvent gives a solid residue which is recrystallized from ether - n-hexane to give an off-white solid. Yield 1.5 g (29.2%); mp 124-125 °C.

EXAMPLE 10

2-[(2,6-dichlorophenyl)amino]-N-hydroxybenzamide.

According to the procedure of Example 1, 2-[(2,6-dichlorophenyl)amino]benzoic acid (J. S. Kaltenbronn, et al., *Arzneimittel-Forschung/Drug Research*, 33(1), 4a, 621-627 (1983)) (4.1 g) is reacted with hydroxylamine hydrochloride (4.04 g) to provide 2-[(2,6-dichlorophenyl)amino]-N-hydroxybenzamide (2.9 g, 67%); mp 171-173 °C. Analysis:

Calc.	C, 52.54;	H, 3.40;	N, 9.43;	Cl, 23.86
Found	C, 52.28;	H, 3.28;	N, 9.39;	Cl, 23.64

EXAMPLE 11

N-hydroxy-2-(phenylamino)benzamide.


A solution of N-phenylanthranilic acid (5.0 g, 23.4 mmol) and carbonyldiimidazole (5.7 g, 35.2 mmol) in dry THF (50 ml) is stirred for two hours at room temperature. O-THP-hydroxylamine (R. N. Warren,

Angewandte Chemie, Int. Ed. Engl. 5, 511 (1966)) (5.5 g, 46.8 mmol) is added and the reaction mixture is cooled, diluted with ethyl acetate (100 ml), and extracted with 0.1 N HCl (2 x 100 ml), saturated aqueous NaHCO₃ (100 ml), and brine (100 ml). The organic layer is dried (MgSO₄) and evaporated. The residue is purified by flash chromatography (silica, 10% CHCl₃/EtOAc). The crude, protected hydroxamate is dissolved in methanol (500 ml) and treated with 10 drops of concentrated HCl. The reaction mixture is stirred for 10 minutes at room temperature and the solvent is evaporated (temperature <35° C). The residue is dissolved in ethyl acetate (200 ml) and washed with saturated aqueous NaHCO₃. The organic layer is dried (MgSO₄) and evaporated. Flash chromatography (silica, EtOAc) gives N-hydroxy-2- (phenylamino)-benzamide (3.5 g, 65%, mp 97-98° C (from isopropyl ether/hexane). Analysis C₁₃H₁₂N₂O₂

Calc.	C, 68.41;	H, 5.30;	N, 12.27
Found	C, 68.45;	H, 5.27;	N, 12.11

The following compounds are prepared according to the procedure in Example 11 from the corresponding carboxylic acids (J. S. Kaltenbrun, et al., Arzneimittel-Forschung/Drug Research, 33(1), 4a, 621-627 (1983)).

5




Example
Number

Ar

mp

% Yield

12



107-112°C

85%

13



amorphous foam

84%


14



amorphous foam

94%


15



105-110°C

75%


16



125-129°C

91%

17




amorphous foam

86%

55

5

10



15
Example
Number

Armp% Yield

20

18




amorphous foam

86%

25

19




97-102°C

60%

30

20




amorphous foam

98%

35

21




amorphous foam

98%

40

22




97-99°C

69%

45

23




amorphous foam

94%

50

24



amorphous foam

96%

55

EXAMPLE 25

N-Hydroxy-N-Methyl-2-[(2,6-dichlorophenyl)amino]benzamide.

According to the procedure of Example 1, 2-[(2,6-dichlorophenyl)amino]benzoic acid (2.0 g) is reacted with N-methylhydroxylamine hydrochloride (2.4 g) to afford N-hydroxy-N-methyl-2-[(2,6-dichlorophenyl)amino]benzamide (1.2 g, 54%), mp 137-140° C. Analysis $C_{14}H_{12}Cl_2N_2O_2$

Calc.	C, 54.04;	H, 3.89;	N, 9.00;	Cl, 22.79
Found	C, 54.13;	H, 3.90;	N, 8.99;	Cl, 22.80

EXAMPLE 26

2,3-Dihydro-3-hydroxy-1-phenyl-4(1H)quinazolinone.


A mixture of N-hydroxy-2-(phenylamino)benzamide (1.4 g, 6.15 mol), p-toluene sulfonic acid (400 mg), and paraformaldehyde (200 mg, 6.75 mmol) in toluene (50 ml) is stirred at room temperature for 30 minutes. The reaction mixture is heated for 10 minutes (in an oil bath preheated to 120-130° C) using a Dean-Stark trap to collect water. The reaction mixture is cooled and diluted with ethyl acetate (50 ml) and is extracted with saturated aqueous $NaHCO_3$ (4 x 50 ml) and water (50 ml). The organic layer is dried ($MgSO_4$) and evaporated. Recrystallization from EtOAc/hexane gives 0.6 g (40%) of 2,3-dihydro-3-hydroxy-1-phenyl-4(1H)-quinazolinone, mp 156-160° C. Analysis $C_{14}H_{12}N_2O_2$

Calc.	C, 69.99;	H, 5.03;	N, 11.66
Found	C, 69.66;	H, 4.95;	N, 11.70

The following compounds are prepared according to the procedure of Example 26.

5


10



15

Example
NumberArmp% YieldPrepared
From
Compound
ofMolecular
Formula

27



131-137°C

10%

Example 12 C₁₆H₁₃F₃N₂O₂

20

28



162-164°C

22%

Example 13 C₁₅H₁₄N₂O₂

25

29




137-143°C

36%

Example 14 C₁₄H₁₁ClN₂O₂

30

30




130-134°C

15%

Example 15 C₁₅H₁₃ClN₂O₂

35

31




133-135°C

7.5%

Example 16 C₁₅H₁₃ClN₂O₂

40

32



128-133°C

19%

Example 17 C₁₄H₁₁ClN₂O₂

45

33



148-150°C

32%

Example 18 C₁₅H₁₄N₂O₃



50

55

5

10	Example Number	Ar	mp	% Yield	Prepared From Compound of	Molecular Formula
	34		179-182°C	28%	Example 19	$C_{14}H_{10}Cl_2N_2O_2$
15						
	35		197-200°C	22%	Example 2	$C_{15}H_{12}Cl_2N_2O_2$
20						
	36		145-150°C dec	5%	Example 10	$C_{14}H_{10}Cl_2N_2O_2$
25						
	37		135-137°C	27%	Example 20	$C_{14}H_{10}Cl_2N_2O_2$
30						
	38		166-168°C	28%	Example 21	$C_{15}H_{11}F_3N_2O_2$
35						
	39		133-135°C	19%	Example 22	$C_{15}H_{11}F_3N_2O_2$
40						
	40		139-142°C	30%	Example 9	$C_{16}H_{16}N_2O_2$
45						
	41		174-176°C	15%	Example 23	$C_{13}H_{14}N_2O_2$
50						

55

Example Number	Ar	mp	% Yield	Prepared From Compound of	Molecular Formula
42		108-110°C	28%	Example 24	C ₁₅ H ₁₄ N ₂ O ₂ 0.1 H ₂ O
43		amorphous foam	10	Example 4	C ₁₆ H ₁₁ Cl ₂ N ₂ O ₂

EXAMPLE 44

1-(2,6-Dichloro-3-methylphenyl)-3-hydroxy-2,4-(1H,3H)quinazolinedione.

2-[2,6-dichloro-3-methylphenyl]aminobenzoic acid (10.0 g) and DMF (2.5 g) are cooled to 0°C in 200 ml CH₂Cl₂ under argon. Oxalyl chloride (9.4 g) is added dropwise at 0°C. When the initial slurry dissolves, the solution is cannulated into a THF solution of O-tetrahydropyranyl hydroxylamine (11.9 g) and triethylamine (20.5 g) at room temperature. The reaction is stirred at room temperature overnight. The solvent is evaporated and the residue is partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer is washed with saturated sodium bicarbonate and dried (MgSO₄). Evaporation gives a solid residue which is recrystallized from isopropyl ether to give 8 g of the O-tetrahydropyranyl hydroxamic acid, mp 148-150°C. It is taken up in THF and treated with NaH (0.48 g) at 0°C for 30 minutes. The reaction is warmed to room temperature and ethylchloroformate is added. After one hour, NaH (0.48 g) is added and the reaction is warmed to reflux for two hours. The reaction is quenched with water and extracted with ethyl acetate. The ethyl acetate layer is washed with brine and dried (MgSO₄). Evaporation of ethyl acetate gives 6.0 g of the 3-O-tetrahydropyranyl quinazolinedione. Two grams of the THP quinazolinedione is taken up in methanol and acidified to pH 1 with concentrated HCl. The reaction is stirred at room temperature overnight. The methanol is evaporated and the residue is taken up in ethyl acetate. It is washed with saturated sodium bicarbonate and dried (MgSO₄). The solvent is evaporated and the residue is recrystallized from isopropyl ether/hexane. Yield of 1-(2,6-dichloro-3-methylphenyl)-3-hydroxy-2,4-(1H,3H)-quinazolinedione = 0.6 g (37%), mp 212-213°C. Analysis C₁₅H₁₀Cl₂N₂O₃

Calc.	C, 53.43;	H, 3.00;	N, 8.31;	Cl, 21.03
Found	C, 53.49;	H, 2.90;	N, 8.22;	Cl, 20.84

EXAMPLE 45

1-(2,6-Dichloro-3-methylphenyl)-3-methoxy-2,4-(1H,3H)quinazolinedione.

2-[(2,6-Dichloro-3-methylphenyl)amino]-N-methoxybenzamide (1.6 g) is added to a THF (20 ml) solution of NaHCO₃ (0.14 g) and ethyl chloroformate (0.25 g) at -30 °C under argon. The reaction is allowed to stir overnight. The THF is evaporated and the residue is partitioned between diethyl ether and water. The organic layer is washed twice with water and brine after being dried over magnesium sulfate. The organic layer is concentrated to give a white solid, which is dissolved in THF and treated with sodium hydride at reflux for one hour under argon. The reaction is acidified with 1 N HCl and partitioned between ethyl acetate and water. The organic layer is washed with brine and dried (MgSO₄). The solvent is evaporated and the residue is adsorbed onto a silica gel pad. The pad is washed with chloroform to give the product. Recrystallization from CH₂Cl₂/Et₂O gives 0.64 g (52% yield) of 1-(2,6-dichloro-3-methylphenyl)-3-methoxy-2,4-(1H,3H)-quinazolinedione, mp 211-213 °C. Analysis C₁₆H₁₂Cl₂N₂O₂

Calc.	C, 54.72;	H, 3.45;	N, 7.98;	Cl, 20.19
Found	C, 54.90;	H, 3.54;	N, 7.99,	Cl, 20.16

EXAMPLE 46

(2',6'-Dichloro-3'-methyl)diphenylamine.

A solution of meclofenamic acid (35 g) in quinoline (100 ml) with copper powder (3.0 g) is heated at reflux (bath temperature 240 °C) under an argon atmosphere for two hours. The reaction mixture is cooled and poured over ice water (350 ml). It is acidified by careful addition of concentrated HCl (85 ml) and extracted with ether. The organic layer is dried (MgSO₄) and evaporated. Flash chromatography (silica, CH₂Cl₂) followed by recrystallization from petroleum ether provides (2',6'-dichloro-3'-methyl)diphenylamine (21 g, 69%), mp 77-79 °C.

EXAMPLE 47

1-(2,6-Dichloro-3-methylphenyl)-1H-indole-2,3-dione.

According to the procedure of A. Sallmann and R. Pfister (U.S. Patent No. 4,092,430), a solution of (2',6'-dichloro-3'-methyl)diphenylamine (20 g) and dimethylaminopyridine (390 mg) and oxalylchloride (15 ml) in chloroform (200 ml) is heated at reflux for 16 hours. The reaction mixture is cooled, evaporated, and redissolved in dichloroethane (150 ml). The resulting solution is added to a suspension of AlCl₃ (32 g) in dichloroethane. The reaction mixture is stirred at room temperature under an argon atmosphere for 20 hours. The reaction mixture is poured over ice water (500 ml) and the layers are separated. The aqueous layer is washed with CHCl₃ and the combined organic layers are evaporated. Chromatography (silica, CHCl₃) affords pure 1-(2,6-dichloro-3-methylphenyl)-1H-indole-2,3-dione (12.9 g, 53%), mp 164-166 °C.

EXAMPLE 48

1-(2,3-Dimethylphenyl)-1H-indole-2,3-dione and 6,7-Dimethyl-1-phenyl-1H-indole-2,3-dione.

According to the procedure of Example 47, (2',3'-dimethyl)diphenylamine (10 g) is reacted with oxalyl chloride to give a mixture of 1-(2,3-dimethylphenyl)-1H-indole-2,3-dione and 6,7-dimethyl-1-phenyl-1H-indole-2,3-dione. Flash chromatography (silica, CHCl₃) provides pure 1-(2,3-dimethylphenyl)-1H-indole-2,3-dione (0.82 g, 6%), mp 183-187 °C and 6,7-dimethyl-1-phenyl-1H-indole-2,3-dione (4.4 g, 35%), mp 147-149 °C.

EXAMPLE 49

5 1-(2,6-Dichloro-3-methylphenyl)-1H-indole-2,3-dione-3-oxime.

A solution of 1-(2,6-dichloro-3-methylphenyl)-1H-indole-2,3-dione (0.3 g) and hydroxylamine hydrochloride (0.07 g) in pyridine (2 ml) is stirred at room temperature for 20 minutes. The reaction mixture is diluted with ethyl acetate (20 ml) and washed with 1 N HCl (2 x 100 ml). The organic layer is dried (MgSO₄) and
 10 evaporated. Flash chromatography (silica, CH₂Cl₂) followed by recrystallization from isopropyl ether affords 1-(2,6-dichloro-3-methylphenyl)-1H-indole-2,3-dione 3-oxime (256 mg, 80%), mp 190-191° C. Analysis C₁₅H₁₀Cl₂N₂O₂

15

Calc.	C, 56.10;	H, 3.14;	N, 8.72;	Cl, 22.08
Found	C, 56.20;	H, 3.12;	N, 8.76;	Cl, 22.0

20

EXAMPLE 50

25 6,7-Dimethyl-1-phenyl-1H-indole-2,3-dione-3-oxime.

According to the procedure of Example 49, 6,7-dimethyl-1-phenyl-1H-indole-2,3-dione (2 g) is converted to 6,7-dimethyl-1-phenyl-1H-indole-2,3-dione-3-oxime (1.2 g, 56%), mp 245-250° C dec. Analysis C₁₆H₁₄N₂O₂

30

Calc.	C, 72.16;	H, 5.30;	N, 10.52
Found	C, 71.78;	H, 5.25;	N, 10.41

35

EXAMPLE 51

40 1-(2,3-Dimethylphenyl)-1H-indole-2,3-dione-3-oxime.

According to the procedure of Example 49, 1-(2,3-dimethylphenyl)-1H-indole-2,3-dione (0.65 g), is converted to 1-(2,3-dimethylphenyl)-1H-indole-2,3-dione-3-oxime (0.5 g, 63%), mp 215-216° C. Analysis
 45 Analysis C₁₆H₁₄N₂O₂

Calc.	C, 72.16;	H, 5.30;	N, 10.52
Found	C, 71.92;	H, 5.07;	N, 10.51

50

EXAMPLE 52

55

2-[(2,6-Dichloro-3-methylphenyl)amino]- α -(hydroxylmino)benzene acetic acid.

A solution of 1-(2,6-dichloro-3-methylphenyl)-1H-indole-2,3-dione-3-oxime (2.25 g) in 6 N NaOH (10 ml)

and 4 ml MeOH is heated at 50°C for two days without a reflux condenser. The resulting residue is taken up in water (50 ml) and filtered. It is neutralized with 1 N HCl with ice bath cooling. The precipitate is collected by filtration. The residue is air dried, dissolved in ether, and filtered. 2-[(2,6-Dichloro-3-methylphenylamino)- α -(hydroxylimino)-benzeneacetic acid (0.28 g, 50%) is precipitated from the ether solution by the addition of hexane, mp 152-154°C dec.

The usefulness of the compounds of the present invention as inhibitors of the 5-lipoxygenase enzyme, cyclooxygenase, or other related biochemical actions may be demonstrated by their effectiveness in various standard test procedures. A description of each procedure follows.

ARBL/ARBC Whole Cell 5-Lipoxygenase and Cyclooxygenase Assays

Materials

The rat basophilic leukemia cell line (RBL-1) was obtained from the American Type Culture Collection (Rockville, MD).

Radioimmuno assay (RIA) kits of LTB₄ and PGF_{2 α} were obtained from Amersham (Arlington Heights, IL) and Seragen (Boston, MA) respectively.

All tissue culture media were obtained from GIBCO (Grand Island, NY).

Method

RBL-1 cells are grown in suspension culture in Eagle's minimum essential medium supplemented with 12% fetal bovine serum at 37°C in an incubator supplied with air-5% carbon dioxide. Cells are harvested by centrifugation. They are washed with cold phosphate buffered saline pH 7.4 (PBS; NaCl, 7.1 g; Na₂HPO₄, 1.15 g; KH₂PO₄, 0.2 g; and KCl, 0.2 g/l). Cells are finally suspended in PBS containing 1.0 mM calcium at a density of 2x10⁶ cells/ml. Cells are incubated with and without test agent (in DMSO) (1% DMSO is without effect on arachidonic acid metabolism) for ten minutes at room temperature. Calcium ionophore A23187 (5 μ M) is added and cells are incubated for seven minutes at 37°C. The reaction is stopped by chilling the tubes on ice for ten minutes. Cells are separated by centrifugation and the supernatant is stored at -20°. Aliquots (100 μ l) are analyzed for LTB₄ and PGF_{2 α} using radioimmuno assay kits as provided by the supplier.

Table 1 contains biochemical data obtained from this whole cell assay as IC₅₀s which are calculated as the amount of test compound causing 50% inhibition of LTB₄ or PGF_{2 α} formation.

Table 1

Entry	ARBL ^{a,b}	ARBC ^{a,c}
Example 2	3.9	1.1
Example 3	1.5	15.0
Example 4	16.0	0.55
Example 10	88% @ 16 μ M	80% @ 16 μ M
Example 9	1.8	60% @ 0.5 μ M
Example 35	3.2	2.2
Example 49	6.5	28
Meclomen	24.0	0.10

^aData are expressed as IC₅₀ values (μ M) for inhibition of substrate conversion to product.

^bIC₅₀ for LTB₄ inhibition.

^cIC₅₀ for PGF_{2 α} inhibition.

Carrageenan-Induced Rat Foot Paw Edema-2 (CFE-2) Assay: Protocol

Carrageenan solution (1% w/v) is prepared by dissolving 100 mg carrageenan (Marine Colloidal Div., Springfield, NJ) in 10 ml of sterile saline (0.9%) solution (Travenol). The solution is vortexed for 30 to 45 minutes. Animals are dosed with compound one hour before carrageenan challenge. Foot paw edema is induced by injecting 0.05 ml of the 1% carrageenan subcutaneously into the plantar portion of the right hind paw of each rat under light anesthesia. Initial foot paw volume is measured immediately following carrageenan challenge using mercury plethysmography (Buxco Electronics). Edema is measured five hours after carrageenan. The difference between the five-hour and the initial paw volume is expressed as delta edema. The delta edema for each test group of animals is used to calculate the percent inhibition of edema achieved by the compound at the test dose compared with the vehicle control group. The ID_{25} (the dose at which swelling is inhibited by 25%) was calculated by probit analysis for the dose at which a result of 25 percent inhibition occurs.

15

Mycobacterium - Induced Rat Footpad Edema Assay (MFE): Protocol

Mycobacterium butyricum (5 mg/ml) is suspended in paraffin oil by sonication for ten minutes in an ice bath. Footpad edema is induced on Day 0 by injecting 0.1 ml of the Mycobacterium mixture into the left hindpaw of lightly anesthetized rats. Swelling in the injected hindpaw is determined by mercury plethysmography 72 hours after injection. Groups of rats are treated with test compounds (suspended in 0.5% hydroxypropyl methylcellulose with 0.2% Tween-80) or vehicle one hour before Mycobacterium injection and on Days 1 and 2. Inhibition of swelling is determined by comparing the change in hindpaw volume in compound- and vehicle-treated rats. An ID_{40} (the dose at which swelling is inhibited by 40%) was calculated by probit analysis.

30 Gastric Ulcerogenicity (UD)

Protocol

35

Male outbred Wistar rats (100-250 gms) were fasted for 24 hours. After fasting, test compounds were administered orally (in 2 ml/kg of 0.5% hydroxypropyl methylcellulose) and the rats were denied access to food and water for six more hours. The rats were then sacrificed with CO_2 so that the stomachs could be removed, opened along the greater curvature, and evaluated for the presence of gastric ulcers. Results are expressed as the percent of rats with gastric ulcers at a given dose.

The results of the CFE-2, MFE, and UD assays for each of the noted compounds is shown in the following Table 2.

45

50

55

Tabl 2

In Vivo Pharmacology			
Entry	CFE-2 ^a	MFE ^b	UD ₅₀ ^c
Example 1	T ^d	27.0	N @ 200
Example 2	0.2	2.5	N @ 200
Example 3	1.3	24.0	N @ 200
Meclomen	8.2	0.39	36.0

^aID₂₅ in mg/kg PO.

^bID₄₀ in mg/kg PO.

^cDose in mg/kg PO which produces a 50% occurrence of ulcers in rats.

N is 0% of rats have ulcers occurring at 200

mg.

^dAssay was not validated by standard.

Accordingly, the present invention is

(a) a compound of formula (I) or an acid addition or base addition salt thereof;

(b) a method for preparing a compound of formula (I) or a pharmacologically acceptable acid addition or base salt thereof;

(c) a pharmaceutical formulation comprising a compound of formula (I) or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier therefor;

(d) a method for preparing such formulations;

(e) a method for the inhibition of the lipoygenase and/or cyclooxygenase pathways of the arachidonic acid metabolism by use of a nontoxic, effective, inhibitory amount of a compound of formula (I) or a physiologically acceptable salt thereof;

(f) a method for the prophylaxis or treatment of disease in a mammal, including man, comprising the administration to said mammal of a nontoxic, therapeutically or prophylactically effective amount of a compound of formula (I) or a physiologically acceptable salt thereof;

(g) a method for the prophylaxis or treatment of any individual condition described herein, in a mammal, including man, comprising the administration to said mammal of a nontoxic therapeutically or prophylactically effective amount of a compound of formula (I) or a physiologically acceptable salt thereof;

(h) a method for the prophylaxis or treatment of asthma in a mammal, including man, comprising administration to said mammal of a nontoxic, effective, antiasthmatic amount of a compound of formula (I) or a physiologically acceptable salt thereof;


(i) a compound of formula (I) or a physiologically acceptable salt thereof for use in medicine, especially as defined in (f)-(h) above;

(j) use of a compound of formula (I) or a physiologically acceptable salt thereof in the manufacture of medical therapeutic agents, particularly those for use as defined in (f)-(h) above; and

(k) any novel feature described herein.


Claims

1. A compound of the formula (I)



wherein

20 (1) R_1 is




wherein R_6 is hydrogen

30 lower alkyl, aryl, aralkyl, or cycloalkyl of from three to ten carbons having three to seven ring carbons, R_7 is H, lower alkyl, acyl, and R_8 is H or lower alkyl; with the proviso that when R_1 is



40 R_7 cannot be methyl when R_5 is para-chloro and R_3 and R_4 are hydrogen; or (iii) as defined together with R_2 below;

(2) R_2 is hydrogen, lower alkyl, or taken together with R_1 is




wherein L_1 is H_2 or oxygen; and R_7 is independently as defined above;

(3) R_2 , R_4 , R_5 , and R_{11} are independently H, fluoro, chloro, bromo, trifluoromethyl, lower alkyl, CN, hydroxy, lower alkoxy, $-S(O)_n$ -lower alkyl wherein n is an integer of 0 through 2, NO_2 or NR_9R_{10} wherein

55 R_9 or R_{10} are independently hydrogen, lower alkyl, or acyl; NO_2 with a further proviso that when R_1 is $C(=O)NHOH$ then R_3 , R_4 , or R_5 cannot all be hydrogen or then one or two of R_3 , R_4 , or R_5 cannot be alkyl when the other one or two of R_3 , R_4 , and R_5 is hydrogen, and when R_1 is

$\text{C}(\text{O})\text{NHOH}$ and one of R_3 , R_4 , or R_5 is ortho-alkyl then one other of R_3 , R_4 , or R_5 cannot be meta-nitro, meta-difluoromethyl, or meta-trifluoromethyl when R_{11} is H, Br, Cl, or nitro; and pharmaceutically acceptable acid addition or base salts thereof.


2. A compound of Claim 1 of the formula



wherein R_1 , R_{11} , R_2 , and R_5 are as defined above and R_3 and R_4 are fluoro, chloro, bromo, trifluoromethyl, or lower alkyl.


3. A compound of Claim 2 wherein R_{11} is hydrogen or lower alkyl.

4. A compound of Claim 1 wherein R_1 is




and R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_{11} are as defined above.

5. A compound of Claim 1 wherein R_1 is




and R_2 , R_3 , R_4 , R_5 , R_7 , and R_8 are as defined above.

6. A compound of Claim 1 wherein R_1 is taken together with R_2 and is




wherein R_3 , R_4 , R_5 , and R_7 are as defined above.

7. A compound of Claim 1 wherein R_1 and R_2 are taken together and are



wherein R_3 , R_4 , and R_5 are as defined above.

8. A compound of Claim 1 wherein R_1 is taken together with R_2 and is



wherein R_3 , R_4 , R_5 , and R_7 are as defined above.

9. A compound of Claim 4 which is a member of the group consisting of 2-((2,6-dichloro-3-methylphenyl)amino)-N-hydroxybenzamide, 2-((2,6-dichloro-3-methylphenyl)amino)-N-methoxybenzamide, 2-((2,6-dichloro-3-methylphenyl)amino)-N-hydroxy-N-methylbenzamide, 2-((2,6-dichloro-3-methylphenyl)amino)-N-hydroxy-N-phenylmethylbenzamide, 2-((2,6-dichloro-3-methylphenyl)amino)-N-hydroxy-N-(1-methylethyl)benzamide, 2-((2,3-dimethylphenyl)amino)-N-hydroxy-N-methylbenzamide, 2-((2,3-dimethylphenyl)amino)-N-methoxybenzamide, 2-((2,3-dimethylphenyl)amino)-N-hydroxy-N-(1-methylethyl)-benzamide, 2-((2,6-dichlorophenyl)amino)-N-hydroxybenzamide, N-hydroxy-2-((4-chlorophenyl)amino)benzamide, N-hydroxy-2-((2-methyl-3-chlorophenyl)amino)benzamide, N-hydroxy-2-((2-chloro-3-methylphenyl)amino)benzamide, N-hydroxy-2-((3-chlorophenyl)amino)benzamide, N-hydroxy-2-((4-methoxyphenyl)amino)benzamide, 2-((3,4-dichlorophenyl)amino)-N-hydroxybenzamide, N-hydroxy-2-((2,3-dichlorophenyl)amino)benzamide, N-hydroxy-2-((2-trifluoromethylphenyl)amino)benzamide, N-hydroxy-2-((3-(trifluoromethyl)phenyl)amino)benzamide and N-hydroxy-N-methyl-2-((2,6-dichlorophenyl)amino)benzamide.


10. A compound of Claim 6 which is a member of the group consisting of 2,3-dihydro-3-hydroxy-1-phenyl-4(1H)-quinazolinone, 2,3-dihydro-3-hydroxy-1-(2-methyl-3-trifluoromethylphenyl)-4(1H)-quinazolinone, 2,3-dihydro-3-hydroxy-1-(4-methylphenyl)-4(1H)-quinazolinone, 1-(4-chlorophenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 1-(3-chloro-2-methylphenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 1-(2-chloro-3-methylphenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 1-(3-chlorophenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 2,3-dihydro-3-hydroxy-1-(4-methoxyphenyl)-4(1H)-quinazolinone, 1-(3,4-dichlorophenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 1-(2,6-dichloro-3-methylphenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone or the monosodium salt thereof, 1-(2,6-dichlorophenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 1-(2,3-dichlorophenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 2,3-dihydro-3-hydroxy-1-(2-(trifluoromethyl)phenyl)-4(1H)-quinazolinone, N-hydroxy-2-((3-(trifluoromethyl)phenyl)amino)benzamide, 1-(2,3-dimethylphenyl)-2,3-dihydro-3-hydroxy-4(1H)-quinazolinone, 2,3-dihydro-3-hydroxy-1-(2-methylphenyl)-4(1H)-quinazolinone, 2,3-dihydro-3-hydroxy-1-(3-methylphenyl)-4(1H)-quinazolinone, 1-(2,6-dichloro-3-methylphenyl)-3-methoxy-4(1H)-quinazolinone.

11. A compound of Claim 8 which is a member of the group consisting of 1-(2,6-dichloro-3-methylphenyl)-3-hydroxy-2,4-(1H,3H)-quinazolinone and 1-(2,6-dichloro-3-methylphenyl)-3-methoxy-2,4-(1H,3H)-quinazolinone.


12. A compound of Claim 7 which is a member of the group consisting of 1-(2,6-dichloro-3-methylphenyl)-1H-indole-2,3-dione-3-oxime, 6,7-dimethyl-1-phenyl-1H-indole-2,3-dione-3-oxime and 1-(2,3-dimethylphenyl)-1H-indole-2,3-dione-3-oxime.

13. A compound of Claim 5 which is 2-((2,6-dichloro-3-methylphenyl)amino)-a-(hydroxylimino)benzene acetic acid.


14. A pharmaceutical composition for inhibiting 5-lipoxygenase or cyclooxygenase which comprises an amount effective for inhibiting 5-lipoxygenase or cyclooxygenase of a compound of the formula (I)



15 and a pharmaceutically acceptable acid addition or base salt thereof; wherein R₁ is (i)



R₆ is hydrogen, lower alkyl, aryl, aralkyl, or cycloalkyl of from three to ten carbons having three to seven ring carbons, R₇ is H, lower alkyl, acyl, and R₈ is H or lower alkyl; or (iii) as defined together with R₂ below; R₂ is hydrogen, lower alkyl, or taken together with R₁ is



wherein L₁ is H₂ or oxygen; and R₇ is independently as defined above;

40 R₃, R₄, R₅, and R₁₁ are independently hydrogen, fluoro, chloro, bromo, trifluoromethyl, lower alkyl, CN, hydroxy, lower alkoxy, -S(O)_n-lower alkyl wherein n is an integer of 0 through 2, NO₂, or NR₉R₁₀ wherein R₉ or R₁₀ are independently hydrogen, lower alkyl, or acyl; with a further proviso that when R₁ is

45
$$\begin{array}{c} \text{O} \\ || \\ \text{CNHOH} \end{array}$$
 then R₃, R₄, or R₅ cannot all be hydrogen or then one or two of R₃, R₄, or R₅ cannot be alkyl when the other one or two of R₃, R₄, and R₅ is hydrogen, and when R₁ is


$$\begin{array}{c} \text{O} \\ || \\ \text{CNHOH} \end{array}$$
 and one of R₃, R₄, or R₅ is ortho-alkyl then one other of R₃, R₄, or R₅ cannot be meta-nitro, meta-difluoromethyl, or meta-trifluoromethyl when R₁₁ is H, Br, Cl, or nitro; and a pharmaceutically acceptable carrier.

50

15. A method for preventing or treating a condition which is advantageously affected by inhibition of 5-lipoxygenase or cyclooxygenase in a mammal suffering from the condition which comprises administering a composition of Claim 7 in unit dosage form.


16. A process for preparing a compound of the formula (I) of Claim 1 which comprises

55 (1) for a compound wherein R₁ is



5

(a) treating a compound of the formula (II)




10

15

20

with oxalyl chloride to obtain a compound of the formula (III)



25

30

35

wherein R₂ is hydrogen, lower alkyl or a protecting group;

(b) the compound (III) is then treated with an hydroxylamine of the formula (IV)

40




IV

45


(2) for a compound wherein R₁ is

50




or is taken together with R₂ and is



55




(a) a compound of the formula (X)



15 is prepared by decarboxylating a compound of the formula (II) above wherein R_2 is H; then
 (b) the compound of formula (X) is treated with




35 (c) then the compound of formula (XI) is cyclized by treatment with a Lewis acid to obtain the compound of formula (I) wherein L_2 is O and
 (d) optionally, (ii) the product of step (c) is further treated with H_2NOR_7 to obtain the compound of formula (I) wherein L_2 is NOR_7 which may optionally be further treated with the nucleophile $:\text{OR}_8$ to obtain the compound of the formula




and

(3) for a compound wherein R_1 is

55




(a) a compound of the formula (I) wherein R_1 is



wherein R'_7 is hydrogen, alkyl, acyl, or a protecting group and R'_6 is hydrogen; is treated with a compound



to obtain a compound of the formula (I) wherein L_1 is oxygen or
(b) alternatively, a compound of the formula (I) wherein R_1 is



wherein R'_7 and R'_6 are as defined above, is treated with formaldehyde to obtain a compound of the formula (I) wherein L_1 is H_2 .

17. Use of a compound of Claims 1 to 13 for the preparation of a pharmaceutical for preventing or treating a condition which is advantageously effected by inhibition of 5-lipoxygenase or cyclooxygenase in a mammal.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 11 7847

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
D,X	JUSTUS LIEBIGS ANNALEN DER CHEMIE, part 7/8, 1975, pages 1245-1251, Weinheim, DE; E. Wolf et al.: "Cyclisierungsreaktionen von am Aminostickstoff substituierten o-Aminobenzhydroxamsäure-O-methylestern" * Page 1247, compound 1'g *	1,4	C 07 C 87/50 C 07 C 131/00 C 07 D 239/92 C 07 D 239/96 C 07 D 209/40 A 61 K 31/165 A 61 K 31/505 A 61 K 31/40
D,X	CHEMICAL ABSTRACTS, vol. 70, no. 3, 20th January 1969, page 25, no. 11330d, Columbus, Ohio, US; & JP-A-67 24 578 (TAKEDA CHEMICAL IND., LTD) 25-11-1967 * Abstract *	1,4	
D,X	CHEMICAL ABSTRACTS, vol. 73, no. 1, 6th July 1970, page 500, no. 10333g, Columbus, Ohio, US; L. DIVIS: "Analytically important reactions of isatin oximes", & SB. VYS. SK. CHEM.-TECHNOL. PRAZE, ANAL. CHEM. 1968, 3, 85-112 * Abstract * & COLLECTIVE SUBJECT INDEX, vol. 66-75, 1967-1971, page 158825, Indole-2,3-dione, 1-phenyl-3-oxine -----	1,7	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 07 C 87/00 C 07 C 131/00 C 07 D 239/00 C 07 D 209/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 27-02-1989	Examiner GAUTIER R.H.A.
CATEGORY F CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	

EPO F RM 150 (02) (P0401)